Neuroprotective Agents (pharmacology) < Neuroprotective Agents (therapeutic use) < Neuroprotective agent

Facettes :

List of bibliographic references indexed by Neuroprotective Agents (therapeutic use)

Number of relevant bibliographic references: 31.
[0-20] [0 - 20][0 - 31][20-30][20-40]

Ident.	Authors (with country if any)	Title
000804 (2014)	P. Cesaro [France] ; L. Defebvre [France]	[Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].
000847 (2014)	Anthony H V. Schapira [Royaume-Uni] ; C Warren Olanow [États-Unis] ; J Timothy Greenamyre [États-Unis] ; Erwan Bezard [France]	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.
000854 (2014)	David Devos [France] ; Caroline Moreau ; David Maltête ; Romain Lefaucheur ; Alexandre Kreisler ; Alexandre Eusebio ; Gilles Defer ; Thavarak Ouk ; Jean-Philippe Azulay ; Pierre Krystkowiak ; Tatiana Witjas ; Marie Delliaux ; Alain Destée [France] ; Alain Duhamel ; Régis Bordet ; Luc Defebvre [France] ; Kathy Dujardin	Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
000883 (2014)	V. Procaccio [France] ; C. Bris [France] ; J M Chao De La Barca [France] ; F. Oca [France] ; A. Chevrollier [France] ; P. Amati-Bonneau [France] ; D. Bonneau [France] ; P. Reynier [France]	Perspectives of drug-based neuroprotection targeting mitochondria.
000D14 (2013)	M. Amalric [France] ; S. Lopez ; C. Goudet ; G. Fisone ; G. Battaglia ; F. Nicoletti ; J-P Pin ; F C Acher	Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
000E86 (2013)	Fanny Duval [France] ; Olivier Flabeau [France] ; Julien Razafimahefa [France] ; Umberto Spampinato [France] ; François Tison [France]	Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: Possible serotonin syndrome
000F10 (2013)	Erwan Bezard [France] ; Zhenyu Yue [États-Unis] ; Deniz Kirik [Suède] ; Maria Grazia Spillantini [Royaume-Uni]	Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies
001094 (2012)	Mickael Decressac [France] ; Stéphanie Pain ; Pierre-Yves Chabeauti ; Laura Frangeul ; Nathalie Thiriet ; Herbert Herzog ; Jackie Vergote ; Sylvie Chalon ; Mohamed Jaber ; Afsaneh Gaillard	Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
001953 (2010)	D. Devos [France] ; R. Bordet ; L. Defebvre	[Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].
001F05 (2009)	Etienne C. Hirsch [France] ; Stéphane Hunot	Neuroinflammation in Parkinson's disease: a target for neuroprotection?
001F68 (2009)	Olivier Rascol [France]	"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
002286 (2008)	Gilbert Bensimon [France] ; Albert Ludolph [Allemagne] ; Yves Agid [France] ; Marie Vidailhet [France] ; Christine Payan [France] ; P. Nigel Leigh [Royaume-Uni]	Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
002495 (2008)	Grégory Porras [France] ; Erwan Bezard [France]	Preclinical development of gene therapy for Parkinson's disease : Gene therapy for parkinson's disease
002586 (2007)	Soumya Rasouri [France] ; Marie Lagouge ; Johan Auwerx	[SIRT1/PGC-1: a neuroprotective axis?].
002608 (2007)	Pierre Etienne Chabrier [France] ; Michel Auguet	Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent.
002815 (2007)	Laila Amazzal [France] ; Agnès Lapotre [France] ; Frédéric Quignon [France] ; Denyse Bagrel [France]	Mangiferin protects against 1 -methyl -4 -phenylpyridinium toxicity mediated by oxidative stress in N2A cells
002898 (2006)		Rasagiline. Parkinson's disease: a simple me-too.
002913 (2006)	E C Hirsch [France]	How to judge animal models of Parkinson's disease in terms of neuroprotection.
002937 (2006)	Erwan Bezard [France] ; Irene Gerlach ; Rosario Moratalla ; Christian E. Gross ; Reinhard Jork	5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease.
002A84 (2006)	Kathy Dujardin [France] ; David Devos [France] ; Stéphane Duhem [France] ; Alain Destée [France] ; Rose-Marie Marie [France] ; Franck Durif [France] ; Lucette Lacomblez [France] ; Jacques Touchon [France] ; Pierre Pollak [France] ; Jean-Jacques Pere [France]	Utility of the mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease
002D37 (2005)	Stéphane Thobois [France] ; Florence Delamarre-Damier [France] ; Pascal Derkinderen [France]	Treatment of motor dysfunction in Parkinson's disease: an overview

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Neuroprotective Agents (therapeutic use)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Neuroprotective Agents (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Neuroprotective Agents (therapeutic use)
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024